• From the registry
  1. Expected survival or time to withdrawal of life-sustaining treatments expected to be <7 days.
  2. Do Not Intubate order
• 
  3. Home mechanical ventilation (noninvasive ventilation or via tracheotomy) except for continuous positive airway pressure or bi-level positive airway pressure (CPAP/BIPAP) used solely for sleep-disordered breathing
• 
  4. PaO2/FiO2 ? 100 at Screening or noted in the 24 hours before Screening. The PaO2/FiO2 may be estimated from pulse oximetry (Appendix 1) or determined by arterial blood gas
• 
  5. High flow supplemental oxygen using a high flow nasal cannula
• 
  6. Noninvasive positive pressure ventilation
• 
  7. Invasive mechanical ventilation via endotracheal intubation or tracheostomy
• 
  8. Extracorporeal membrane oxygenation (ECMO)
• 
  9. Shock defined by the use of vasopressors
• 
  10. Multiple organ dysfunction or failure
• 
  11. Positive Influenza A or B testing if tested as local standard of care
• 
  12. Pathogens detected by a respiratory panel if tested as local standard of care
• 
  13. The patient has a history of:
  a. Organ or hematologic transplant
• 
  b. HIV
• 
  c.Active hepatitis B, or hepatitis C infection
• 
  14. Current treatment with:
  a. Chemotherapy
• 
  b. Immunosuppressive medications or immunotherapy (Section 5.3 for list of prohibited immunosuppressive medications and immunotherapy) at the time of consent
• 
  c. Hemodialysis or Peritoneal Dialysis
• 
  15. Have a history of venous thromboembolism (VTE) (deep vein thrombosis [DVT] or pulmonary embolism [PE]) within 12 weeks prior to screening or have a history of recurrent (> 1) VTE
• 
  16. The patient is known to be pregnant or is nursing
• 
  17. Currently participating in another study of an investigational drug or therapeutic medical device at the time of consent
• 
  18. Allergy to eggs or any of the excipients in study drug.

Protocol

NR

Statistical plan

NR

Data-sharing willing stated in the publication: